Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein Thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur after knee replacement surgery and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Apixaban; Enoxaparin

Criteria

Key Inclusion Criteria:

• Men and non-pregnant, non-breastfeeding women

• 18 years or older

• Scheduled for knee replacement surgery

Key Exclusion Criteria:

• hereditary or acquired bleeding disorders

• clotting disorders

• bleeding or high risk for bleeding

• drugs that affect bleeding or coagulation

• need for ongoing parenteral or oral anticoagulation